D5191F3D-028E-401C-927E-483F6884BE39
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 10.709592641261498
- age_years
- 58
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C9EE359E-2F42-4D20-880D-FBF8B4953731 | — | — | 0.977 |
| 2 | SRR934965 | — | — | 0.973 |
| 3 | SRR934747 | — | — | 0.972 |
| 4 | AF0A7BAA-D031-4C9F-91B7-7034F2C49D72 | — | — | 0.970 |
| 5 | SRR934926 | — | — | 0.970 |
| 6 | 113D7756-712E-4EB4-9993-BBAF3C41AFEF | — | — | 0.970 |
| 7 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.970 |
| 8 | SRR934835 | — | — | 0.969 |
| 9 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.965 |
| 10 | 795FBB8C-0E74-477F-AA27-1CE97A4E90B9 | — | — | 0.965 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.549 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.532 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.525 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.513 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.513 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.511 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.495 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.489 | Inavolisib | — uncovered |
| HYPOXIA | 0.478 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.471 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.471 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.435 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.424 | Idelalisib | — uncovered |
| APOPTOSIS | 0.422 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.415 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.395 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.374 | Remibrutinib | — uncovered |